RedHill Biopharma Ltd. (RDHL) Stock Score, Valuation & Financial Research
RedHill Biopharma Ltd. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 23/100.
Quick answer for RDHL
RedHill Biopharma Ltd. currently has a Wall Street Score of 23/100. The stored market price is $0.61. Its financial score is 3/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What RedHill Biopharma Ltd. does
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for p
RDHL financial snapshot
- Wall Street Score:
- 23/100
- Current price:
- $0.61
- Market capitalization:
- $1.9M
- Revenue:
- $9.5M
- Net income:
- $-9.3M
- Free cash flow:
- $-9.7M
- Cash:
- $4.0M
- Total debt:
- $1.1M
- EPS:
- 0.00
- Financial score:
- 3/100
- Valuation score:
- 0/100
- Revenue score:
- 40/100
What stands out
- Reported year-over-year revenue growth is +32.4%.
- Free cash flow is $-9.7M, showing cash burn in the current stored period.
- The balance sheet shows $4.0M of cash versus $1.1M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 3/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research RDHL
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.